Preclinical studies have demonstrated the therapeutic potential of CEACAM6, showing that its downregulation suppresses tumor growth and increases cancer-cell sensitivity to chemotherapy [15,17,18]. The gene discussed is CEACAM6; the disease is neoplasm.